Melanoma in children: Diagnosis and treatment specificities;Mélanomecutané de l'enfant: Particularit́es diagnostiques et t́herapeutiques

Bulletin du Cancer

Volumn 99, Issue 9, 2012, Pages 881-888

  Réguerre, Yves ^a   Avril, Marie Françoise ^b   Fraitag, Sylvie ^c   Bodemer, Christine ^c  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b Service de Dermatologie ^*  (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Dermatology; Melanoma; Paediatry; Rare tumor

Indexed keywords

ARTICLE; BENIGN TUMOR; CANCER INCIDENCE; CANCER PROGNOSIS; CHILDHOOD CANCER; CONGENITAL NEVUS; DERMATOLOGIST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOCYTIC NEVUS; MELANOMA; PATHOLOGIST; XERODERMA PIGMENTOSUM; CHILD; PATHOLOGY; PROGNOSIS; RARE DISEASE; SKIN TUMOR;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; CHILD; HUMANS; MELANOMA; PROGNOSIS; RARE DISEASES; SKIN NEOPLASMS;

EID: 84867129672     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2012.1628     Document Type: Article

References (51)

1. Conti EM, Cercato MC, Gatta G, Ramazzotti V, Roscioni S. Childhood melanoma in Europe since 1978: a population-based survival study. Eur J Cancer 2001; 37 : 780-4. (Pubitemid 32304415)
2. Clavel J. Epidemiology of childhood cancers. Rev Prat 2007; 57 : 1061, 1064, 1067-69.
3. Lacour B, Guyot-Goubin A, Guissou S, Bellec S, Desandes E, Clavel J. Incidence of childhood cancer in France: National Children Cancer Registries, 2000-2004. Eur J Cancer Prev 2010; 19 : 173-81.
4. Strouse JJ, Fears TR, Tucker MA, Wayne AS. Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. J Clin Oncol 2005; 23 : 4735-41. (Pubitemid 46224077)
5. Lange JR, Palis BE, Chang DC, Soong SJ, Balch CM. Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J Clin Oncol 2007; 25 : 1363-8. (Pubitemid 46706883)
6. de Vries E, Steliarova-Foucher E, Spatz A, Ardanaz E, Eggermont AM, Coebergh JW. Skin cancer incidence and survival in European children and adolescents (1978-1997). Report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006; 42 : 2170-82. (Pubitemid 44224066)
7. Hamre MR, Chuba P, Bakhshi S, Thomas R, Severson RK. Cutaneous melanoma in childhood and adolescence. Pediatr Hematol Oncol 2002; 19 : 309-17. (Pubitemid 34633365)
8. Karlsson PM, Fredrikson M. Cutaneous malignant melanoma in children and adolescents in Sweden, 1993-2002: the increasing trend is broken. Int J Cancer 2007; 121 : 323-8. (Pubitemid 46917701)
9. Baade PD, Green AC, Smithers BM, Aitken JF. Trends in melanoma incidence among children: possible influence of sun-protection programs. Expert Rev Anticancer Ther 2011; 11 : 661-4.
10. Manganoni AM, Farisoglio C, Tucci G, Facchetti F, Ungari M, Calzavara-Pinton PG. Thin primary cutaneous melanoma in childhood and adolescence: report of 12 cases. Pediatr Dermatol 2009; 26 : 356-7.
11. Ferrari A, Bono A, Baldi M, et al. Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. Pediatrics 2005; 115 : 649-54. (Pubitemid 43373024)
12. Jafarian F, Powell J, Kokta V, et al. Malignant melanoma in childhood and adolescence: report of 13 cases. J Am Acad Dermatol 2005; 53 : 816-22. (Pubitemid 41501367)
13. Richardson SK, Tannous ZS, Mihm Jr. MC. Congenital and infantile melanoma: review of the literature and report of an uncommon variant, pigment-synthesizing melanoma. J Am Acad Dermatol 2002; 47 : 77-90.
14. Alexander A, Samlowski WE, Grossman D, et al. Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. J Clin Oncol 2003; 21 : 2179-86. (Pubitemid 46606367)
15. Leech SN, Bell H, Leonard N, et al. Neonatal giant congenital nevi with proliferative nodules: a clinicopathologic study and literature review of neonatal melanoma. Arch Dermatol 2004; 140 : 83-8. (Pubitemid 38090274)
16. Price HN, Schaffer JV. Congenital melanocytic nevi-when to worry and how to treat: facts and controversies. Clin Dermatol; 28 : 293-302.
17. Spatz A, Avril MF. Melanoma in childhood: review and perspectives. Pediatr Dev Pathol 1998; 1 : 463-74. (Pubitemid 128542163)
18. Spatz A, Calonje E, Handfield-Jones S, Barnhill RL. Spitz tumors in children: a grading system for risk stratification. Arch Dermatol 1999; 135 : 282-5. (Pubitemid 29159210)
19. Stanescu L, Popescu CF, Georgescu I, et al. Spitz nevus with an uncertain malignant potential. Rom J Morphol Embryol 2009; 50 : 275-82.
20. Clarke LE, Fountaine TJ, Hennessy J, et al. Cdc7 expression in melanomas. Spitz tumors and melanocytic nevi. J Cutan Pathol 2009; 36 : 433-8.
21. Fullen DR, Poynter JN, Lowe L, et al. BRAF and NRAS mutations in spitzoid melanocytic lesions. Mod Pathol 2006; 19 : 1324-32. (Pubitemid 44423079)
22. Eigentler TK, Radny P, Kamin A, Weide B, Caroli UM, Garbe C. Experiences with the new American Joint Committee on Cancer (AJCC) classification of cutaneous melanoma. J Dtsch Dermatol Ges 2005; 3 : 592-8. (Pubitemid 41647825)
23. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27 : 6199-206.
24. Lohmann CM, Coit DG, Brady MS, Berwick M, Busam KJ. Sentinel lymph node biopsy in patients with diagnostically controversial spitzoid melanocytic tumors. Am J Surg Pathol 2002; 26 : 47-55. (Pubitemid 34019991)
25. Su LD, Fullen DR, Sondak VK, Johnson TM, Lowe L. Sentinel lymph node biopsy for patients with problematic spitzoid melanocytic lesions: a report on 18 patients. Cancer 2003; 97 : 499-507. (Pubitemid 36133818)
26. Urso C, Borgognoni L, Saieva C, et al. Sentinel lymph node biopsy in patients with "atypical Spitz tumors." A report on 12 cases. Hum Pathol 2006; 37 : 816-23. (Pubitemid 43902939)
27. Busam KJ. Sentinel lymph node biopsy for patients with melanoma-introductory comments. Semin Diagn Pathol 2008; 25 : 83-5. (Pubitemid 351885457)
28. Murali R, Sharma RN, Thompson JF, et al. Sentinel lymph node biopsy in histologically ambiguous melanocytic tumors with spitzoid features (so-called atypical spitzoid tumors). Ann Surg Oncol 2008; 15 : 302-9.
29. LeBoit PE. What do these cells prove? Am J Dermatopathol 2003; 25 : 355-6. (Pubitemid 36897343)
30. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355 : 1307-17. (Pubitemid 44465459)
31. Dalal KM, Patel A, Brady MS, Jaques DP, Coit DG. Patterns of first-recurrence and post-recurrence survival in patients with primary cutaneous melanoma after sentinel lymph node biopsy. Ann Surg Oncol 2007; 14 : 1934-42. (Pubitemid 46870940)
32. Wright BE, Scheri RP, Ye X, et al. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg 2008 ; 143 : 892-9 (discussion 899-900).
33. van der Ploeg AP, van Akkooi AC, Rutkowski P, et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined rotterdam tumor load and dewar topography criteria. J Clin Oncol 2011; 29 : 2206-14.
34. Altman JF, Lowe L, Redman B, et al. Placental metastasis of maternal melanoma. J Am Acad Dermatol 2003; 49 : 1150-4. (Pubitemid 37475498)
35. Perret-Court A, Fernandez C, Monestier S, Millet V, Tasei AM. Placental metastasis of melanoma: a new case and literature review. Ann Pathol 2010; 30 : 143-6.
36. O'Meara AT, Cress R, Xing G, Danielsen B, Smith LH. Malignant melanoma in pregnancy. A population-based evaluation. Cancer 2005; 103 : 1217-26. (Pubitemid 40328093)
37. Jen M, Murphy M, Grant-Kels JM. Childhood melanoma. Clin Dermatol 2009; 27 : 529-36.
38. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004; 10 : 1670-7. (Pubitemid 38435557)
39. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372 : 117-26. (Pubitemid 351952257)
40. Anaya DA, Xing Y, Feng L, et al. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Cancer 2008; 112 : 2030-7. (Pubitemid 351574079)
41. Navid F, Furman WL, Fleming M, et al. The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma. Cancer 2005; 103 : 780-7. (Pubitemid 40216407)
42. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010; 102 : 493-501.
43. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003; 29 : 241-52. (Pubitemid 37069655)
44. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004; 40 : 1825-36. (Pubitemid 39036756)
45. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18 : 158-66. (Pubitemid 30036349)
46. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17 : 2105-16. (Pubitemid 29318842)
47. Daniotti M, Ferrari A, Frigerio S, et al. Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT. J Invest Dermatol 2009; 129 : 1759-68.
48. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363 : 809-19.
49. Chapman PB, Hauschild A, Robert C, et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E mutation. N Engl J Med 2011; 364 : 2507-16.
50. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363 : 711-23.
51. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus Dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364 : 2517-26.